Matthew L Whitlock, MD
Cardiovascular Disease (Cardiology) · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Offices
- 3
Offices
3 locations · Stanford Health Care · Siskiyou Hospital Inc
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Whitlock’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A117923 · Current
Licensed to practise in California · since 2011 · expires 2027-04-30 · University of North Carolina at Chapel Hill.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$33,748
Medicare paid this office $33,748 for 784 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 98 | $13,733 | $110 |
| Long return visit (40+ min) | 30 | $4,960 | $146 |
| Short return visit (20+ min) | 59 | $4,638 | $71 |
| New patient visit (60+ min) | 22 | $4,146 | $188 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 539 | $4,087 | $7 |
See all 7 services
| Return visit (30+ min) | 98 | $13,733 | $110 |
| Long return visit (40+ min) | 30 | $4,960 | $146 |
| Short return visit (20+ min) | 59 | $4,638 | $71 |
| New patient visit (60+ min) | 22 | $4,146 | $188 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 539 | $4,087 | $7 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 70 | $1,390 | $20 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 14 | $157 | $11 |
Who their Medicare patients are
784 Original Medicare patients in 2024. Average age 75 · Under 65 11% · 85 and older 16% · Women 47% · Also on Medicaid 31% · Health risk score 2.22. Above the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Coronary heart disease 47% · Atrial fibrillation 42% · Chronic kidney disease 40% · Diabetes 36% · Heart failure 35% · Depression 27% · Cancer 22% · Dementia 19% · COPD 17% · Stroke 17%.
The office billed $178,411, Medicare allowed $48,216 and paid $33,748; for 956 services of 12 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 784 | 956 | 75 | 2.22 | $178,411 | $33,748 |
| 2023 | 608 | 752 | 75 | 2.32 | $191,022 | $32,064 |
| 2022 | 651 | 874 | 74 | 2.12 | $233,448 | $33,832 |
| 2021 | 811 | 1,205 | 74 | 2.06 | $323,835 | $52,741 |
| 2020 | 567 | 852 | 73 | 2.38 | $240,134 | $33,116 |
| 2019 | 569 | 781 | 73 | 1.97 | $204,571 | $35,906 |
| 2018 | 595 | 918 | 74 | 2.28 | $283,091 | $35,647 |
| 2017 | 173 | 398 | 71 | 2.02 | $221,976 | $31,061 |
| 2016 | 168 | 232 | 73 | 1.76 | $121,271 | $19,644 |
| 2015 | 72 | 72 | 71 | 2.49 | $24,999 | $7,735 |
| 2014 | 56 | 57 | 71 | 1.79 | $21,226 | $7,139 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Return visit (30+ min) | 95 | $13,709 | $115 |
| New patient visit (60+ min) | 34 | $6,564 | $193 |
| Long return visit (40+ min) | 26 | $4,906 | $158 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 412 | $3,150 | $7 |
| Short return visit (20+ min) | 32 | $2,413 | $71 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 37 | $838 | $23 |
2022: 7 services
| Return visit (30+ min) | 94 | $12,617 | $104 |
| Long return visit (40+ min) | 30 | $7,635 | $162 |
| New patient visit (60+ min) | 25 | $4,318 | $173 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 466 | $3,854 | $7 |
| Short return visit (20+ min) | 44 | $3,533 | $69 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 45 | $1,021 | $23 |
| Telehealth originating site facility fee | 30 | $439 | $14 |
2021: 7 services
| Return visit (30+ min) | 99 | $15,707 | $114 |
| New patient visit (60+ min) | 65 | $13,184 | $203 |
| Long return visit (40+ min) | 50 | $9,086 | $159 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 566 | $4,995 | $7 |
| Short return visit (20+ min) | 49 | $4,072 | $75 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 85 | $2,239 | $25 |
| Telehealth originating site facility fee | 75 | $2,063 | $21 |
2020: 7 services
| Return visit (30+ min) | 85 | $13,465 | $95 |
| New patient visit (45+ min) | 29 | $4,191 | $145 |
| New patient visit (60+ min) | 22 | $3,796 | $173 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 389 | $3,324 | $7 |
| Short return visit (20+ min) | 45 | $3,191 | $66 |
| Telehealth originating site facility fee | 64 | $1,636 | $21 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 53 | $1,356 | $23 |
2019: 8 services
| Return visit (30+ min) | 119 | $12,050 | $71 |
| New patient visit (60+ min) | 53 | $8,316 | $157 |
| New patient visit (45+ min) | 31 | $3,644 | $118 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 48 | $3,071 | $64 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 332 | $2,845 | $8 |
| Long return visit (40+ min) | 23 | $2,490 | $104 |
| Short return visit (20+ min) | 30 | $1,637 | $50 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 40 | $1,079 | $25 |
2018: 9 services
| Return visit (30+ min) | 116 | $15,988 | $75 |
| New patient visit (60+ min) | 33 | $4,550 | $138 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 398 | $3,416 | $8 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 46 | $2,865 | $62 |
| Long return visit (40+ min) | 23 | $2,852 | $106 |
| New patient visit (45+ min) | 23 | $2,597 | $113 |
| Short return visit (20+ min) | 20 | $1,046 | $52 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 27 | $654 | $24 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 19 | $125 | $7 |
2017: 7 services
| Return visit (30+ min) | 95 | $15,144 | $81 |
| New patient visit (60+ min) | 46 | $6,643 | $144 |
| Long return visit (40+ min) | 24 | $2,981 | $115 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 49 | $2,653 | $54 |
| New patient visit (45+ min) | 11 | $1,281 | $116 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 16 | $837 | $52 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 11 | $90 | $7 |
2016: 6 services
| New patient visit (45+ min) | 51 | $6,340 | $124 |
| Return visit (30+ min) | 35 | $4,106 | $86 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 54 | $3,037 | $56 |
| New patient visit (60+ min) | 12 | $1,957 | $163 |
| Short return visit (20+ min) | 22 | $1,319 | $57 |
| New patient visit (30+ min) | 13 | $1,149 | $88 |
2015: 2 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 25 | $3,589 | $144 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 15 | $1,093 | $73 |
2014: 2 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 28 | $4,221 | $151 |
| Initial hospital observation care per day, typically 70 minutes | 11 | $1,556 | $141 |
Medicaid work
$4,129 in 2024
Medicaid paid $4,129 for 402 billed services this clinician did in 2024, up to 123 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 402 | $4,129 |
| 2024 | 402 | 1 | 123 | $4,129 |
| 2023 | 484 | 2 | 117 | $5,689 |
| 2022 | 452 | 3 | 90 | $5,818 |
| 2021 | 602 | 2 | 134 | $7,697 |
| 2020 | 331 | 2 | 94 | $4,849 |
| 2019 | 172 | 1 | 90 | $2,025 |
| 2018 | 234 | 1 | 70 | $2,497 |
See the largest Medicaid services in earlier years
2023
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 472 | $5,107 |
| Return visit (30+ min) | 12 | $582 |
2022
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 420 | $4,793 |
| Return visit (30+ min) | 12 | $543 |
| Telehealth originating site facility fee | 20 | $482 |
2021
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 589 | $6,879 |
| Return visit (30+ min) | 13 | $818 |
2020
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 316 | $3,913 |
| Return visit (30+ min) | 15 | $936 |
2019
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 172 | $2,025 |
2018
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 234 | $2,497 |
Drugs they prescribed that Part D paid
$177,929
Pharmacies billed $177,929 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 961) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
810 generic and 151 brand-name prescriptions · $177,929 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 62 | $71,481 | $1,153 |
| Entresto | 22 | $32,615 | $1,483 |
| Jardiance | 21 | $26,953 | $1,283 |
| Xarelto | 20 | $19,132 | $957 |
| Repatha Sureclick | 11 | $5,917 | $538 |
See all 19 drugs
| Eliquis | 62 | $71,481 | $1,153 |
| Entresto | 22 | $32,615 | $1,483 |
| Jardiance | 21 | $26,953 | $1,283 |
| Xarelto | 20 | $19,132 | $957 |
| Repatha Sureclick | 11 | $5,917 | $538 |
| Rosuvastatin | 63 | $1,381 | $22 |
| Metoprolol | 94 | $1,285 | $14 |
| Atorvastatin | 132 | $1,241 | $9 |
| Losartan | 105 | $963 | $9 |
| Amlodipine Besylate | 75 | $433 | $6 |
| Carvedilol | 41 | $416 | $10 |
| Pravastatin | 28 | $392 | $14 |
| Nitroglycerin | 17 | $313 | $18 |
| Lisinopril | 44 | $253 | $6 |
| Furosemide | 44 | $245 | $6 |
| Spironolactone | 30 | $242 | $8 |
| Metoprolol | 18 | $206 | $11 |
| Isosorbide Mononitrate Er | 13 | $152 | $12 |
| Hydrochlorothiazide | 14 | $56 | $4 |
Year by year
| 2024 | 961 | 132 | 0% (0) | 16% | $177,929 |
| 2023 | 957 | 136 | 0% (0) | 14% | $169,137 |
| 2022 | 1,026 | 134 | 0% (0) | 12% | $165,372 |
| 2021 | 933 | 131 | 0% (0) | 16% | $138,232 |
| 2020 | 678 | 104 | 0% (0) | None | $106,743 |
| 2019 | 634 | 104 | 0% (0) | 10% | $60,750 |
| 2018 | 589 | 83 | 0% (0) | 11% | $45,999 |
| 2017 | 390 | 53 | 0% (0) | 18% | $34,627 |
| 2016 | 69 | 26 | 0% (0) | None | $2,889 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 19 drugs
| Eliquis | 69 | $78,484 | $1,137 |
| Xarelto | 21 | $29,871 | $1,422 |
| Jardiance | 16 | $20,078 | $1,255 |
| Entresto | 11 | $16,512 | $1,501 |
| Atorvastatin | 125 | $2,380 | $19 |
| Metoprolol | 100 | $1,931 | $19 |
| Rosuvastatin | 61 | $1,878 | $31 |
| Losartan | 96 | $1,266 | $13 |
| Carvedilol | 44 | $1,003 | $23 |
| Lisinopril | 44 | $772 | $18 |
| Pravastatin | 31 | $460 | $15 |
| Amlodipine Besylate | 54 | $397 | $7 |
| Nitroglycerin | 20 | $328 | $16 |
| Metoprolol | 35 | $327 | $9 |
| Ezetimibe | 18 | $298 | $17 |
| Spironolactone | 26 | $290 | $11 |
| Furosemide | 39 | $258 | $7 |
| Valsartan | 11 | $167 | $15 |
| Hydrochlorothiazide | 14 | $87 | $6 |
2022: 20 drugs
| Eliquis | 60 | $80,728 | $1,345 |
| Xarelto | 16 | $24,780 | $1,549 |
| Metoprolol | 106 | $2,323 | $22 |
| Rosuvastatin | 76 | $2,313 | $30 |
| Atorvastatin | 120 | $1,685 | $14 |
| Eplerenone | 12 | $1,125 | $94 |
| Losartan | 83 | $1,107 | $13 |
| Ezetimibe | 15 | $1,042 | $69 |
| Carvedilol | 50 | $773 | $15 |
| Amlodipine Besylate | 90 | $618 | $7 |
| Nitroglycerin | 19 | $594 | $31 |
| Nebivolol | 12 | $593 | $49 |
| Lisinopril | 51 | $473 | $9 |
| Furosemide | 39 | $445 | $11 |
| Pravastatin | 20 | $390 | $20 |
| Isosorbide Mononitrate Er | 14 | $375 | $27 |
| Spironolactone | 21 | $366 | $17 |
| Clopidogrel | 16 | $243 | $15 |
| Metoprolol | 38 | $240 | $6 |
| Hydrochlorothiazide | 21 | $75 | $4 |
2021: 17 drugs
| Eliquis | 68 | $64,655 | $951 |
| Xarelto | 12 | $18,016 | $1,501 |
| Metoprolol | 98 | $2,451 | $25 |
| Rosuvastatin | 70 | $2,283 | $33 |
| Atorvastatin | 98 | $1,968 | $20 |
| Losartan | 75 | $1,037 | $14 |
| Carvedilol | 65 | $970 | $15 |
| Ezetimibe | 13 | $803 | $62 |
| Amlodipine Besylate | 88 | $744 | $8 |
| Nitroglycerin | 15 | $701 | $47 |
| Pravastatin | 19 | $417 | $22 |
| Lisinopril | 39 | $373 | $10 |
| Spironolactone | 25 | $347 | $14 |
| Furosemide | 29 | $294 | $10 |
| Metoprolol | 28 | $211 | $8 |
| Clopidogrel | 11 | $154 | $14 |
| Hydrochlorothiazide | 19 | $82 | $4 |
2020: 18 drugs
| Eliquis | 50 | $50,449 | $1,009 |
| Xarelto | 15 | $19,449 | $1,297 |
| Rosuvastatin | 42 | $2,617 | $62 |
| Metoprolol | 50 | $1,573 | $31 |
| Ezetimibe | 14 | $1,030 | $74 |
| Atorvastatin | 62 | $999 | $16 |
| Digoxin | 12 | $682 | $57 |
| Losartan | 33 | $508 | $15 |
| Amlodipine Besylate | 72 | $404 | $6 |
| Carvedilol | 49 | $386 | $8 |
| Lisinopril | 34 | $317 | $9 |
| Pravastatin | 17 | $317 | $19 |
| Potassium Chloride | 11 | $281 | $26 |
| Spironolactone | 28 | $279 | $10 |
| Furosemide | 28 | $203 | $7 |
| Clopidogrel | 14 | $158 | $11 |
| Metoprolol | 20 | $122 | $6 |
| Hydrochlorothiazide | 11 | $88 | $8 |
2019: 13 drugs
| Eliquis | 25 | $21,999 | $880 |
| Rosuvastatin | 45 | $3,056 | $68 |
| Atorvastatin | 89 | $1,722 | $19 |
| Metoprolol | 60 | $1,549 | $26 |
| Chlorthalidone | 15 | $661 | $44 |
| Lisinopril | 53 | $586 | $11 |
| Carvedilol | 41 | $416 | $10 |
| Losartan | 39 | $404 | $10 |
| Amlodipine Besylate | 64 | $391 | $6 |
| Pravastatin | 12 | $303 | $25 |
| Isosorbide Mononitrate Er | 12 | $255 | $21 |
| Metoprolol | 23 | $244 | $11 |
| Hydrochlorothiazide | 13 | $77 | $6 |
2018: 16 drugs
| Eliquis | 22 | $13,775 | $626 |
| Bystolic | 13 | $5,914 | $455 |
| Olmesartan Medoxomil | 14 | $1,582 | $113 |
| Atorvastatin | 86 | $1,336 | $16 |
| Metoprolol | 48 | $1,224 | $26 |
| Rosuvastatin | 23 | $1,171 | $51 |
| Chlorthalidone | 11 | $558 | $51 |
| Lisinopril | 58 | $507 | $9 |
| Pravastatin | 26 | $506 | $19 |
| Amlodipine Besylate | 54 | $253 | $5 |
| Clopidogrel | 11 | $193 | $18 |
| Losartan | 19 | $184 | $10 |
| Metoprolol | 20 | $146 | $7 |
| Carvedilol | 16 | $129 | $8 |
| Spironolactone | 14 | $79 | $6 |
| Hydrochlorothiazide | 11 | $58 | $5 |
2017: 11 drugs
| Eliquis | 13 | $8,664 | $666 |
| Bystolic | 18 | $5,182 | $288 |
| Metoprolol | 47 | $1,180 | $25 |
| Atorvastatin | 45 | $713 | $16 |
| Pravastatin | 27 | $313 | $12 |
| Amlodipine Besylate | 37 | $198 | $5 |
| Metoprolol | 12 | $122 | $10 |
| Clopidogrel | 27 | $103 | $4 |
| Lisinopril | 14 | $102 | $7 |
| Carvedilol | 16 | $69 | $4 |
| Losartan | 12 | $58 | $5 |
2016: 1 drug
| Atorvastatin | 13 | $172 | $13 |
Money from drug and device companies
$48 in 2025
| 2025 | 1 | 1 | None | $48 |
| 2024 | 1 | 1 | None | $22 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Edwards Lifesciences | Evoque | $48 | 1 payment
|
See the published payment
| Edwards Lifesciences | Meals · 2025-10-03 | Evoque | $48 |
See earlier years (2024)
2024: $22
| Salix Pharmaceuticals a division of Bausch Health US | Trulance | $22 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1134335060
- Licence
- CA A117923California A117923: Current · expires 2027-04-30
- Trained
- University of North Carolina at Chapel Hill School of Medicine, 2005
- Group
- Stanford Health Care · Siskiyou Hospital Inc
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Cardiology (207RC0000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-05-15
- NPI last updated
- 2024-04-26
- NPI record certified
- 2024-04-26
This is when the NPI record was last certified, not a medical board exam.